Whether Screening for Non-alcoholic Fatty Liver Disease in Patients With Psoriasis Is Necessary: A Pilot Quality Improvement Project

Kader Torbator; Stephanie Poo; Taif Al-Rubaye; Leah Mapara; Sungeeta Punjabi; Ali Al-Rubaye; Laith Alrubaiy

doi:10.7759/cureus.24714

Whether Screening for Non-alcoholic Fatty Liver Disease in Patients With Psoriasis Is Necessary: A Pilot Quality Improvement Project

Cureus. 2022 May 3;14(5):e24714. doi: 10.7759/cureus.24714. eCollection 2022 May.

Authors

Kader Torbator¹, Stephanie Poo¹, Taif Al-Rubaye², Leah Mapara³, Sungeeta Punjabi³, Ali Al-Rubaye⁴, Laith Alrubaiy⁵

Affiliations

¹ Gastroenterology and Hepatology, London Northwest NHS Trust, London, GBR.
² General Practice, Manchester NHS Trust, Manchester, GBR.
³ Dermatology, London Northwest NHS Trust, London, GBR.
⁴ Public Health, Basra Health Directorate, Basra, IRQ.
⁵ Gastroenterology, St Mark's Hospital, London, GBR.

Abstract

Background Psoriasis is a chronic inflammatory skin disease that is strongly associated with non-alcoholic fatty liver disease (NAFLD). Both conditions are associated with excess cardiovascular and liver-related morbidity and mortality. The severity of psoriasis correlates with the degree of liver inflammation and scarring, which can be further exacerbated by systemic immunomodulators such as methotrexate. Currently, no clinical pathway exists to screen psoriasis patients for NAFLD in our Trust. We aimed to develop a shared clinical pathway between our hepatology and dermatology departments to allow early identification and management of NAFLD in this patient group. Methods A multidisciplinary team was assembled to identify patient priorities, management goals, and screening criteria. We identified gaps in our service and reviewed current clinical best practice guidelines. A clinical pathway was developed using a process map and revised according to feedback received. We piloted this pathway on a prospective cohort of psoriasis patients identified by our dermatology department. Patients were invited for transient elastography if fatty liver was identified on an ultrasound scan. Baseline demographics, biochemistry and imaging results were collected and analysed. Results Of 57 psoriasis patients, 30 (52.6%) had sonographic evidence of hepatic steatosis. The median age was comparable between groups with 56 and 55 years in the psoriasis-NAFLD (Ps-NAFLD) and no-NAFLD groups respectively. There were more males in the Ps-NAFLDgroup (56.7%) compared to the no-NAFLD group (37%). Fifteen out of 30 patients were eligible for transient elastography (two were excluded due to body habitus). Seven (53.8%) patients had no-to-mild fibrosis indicated by liver stiffness measurement (LSM) ≤7kPa, while six (46.1%) had moderate-to-severe fibrosis. Three (23.0%) patients had scores suggestive of cirrhosis (LSM>13kPa). Conclusions The introduction of a new shared-care pathway at our Trust has resulted in a streamlined way in which psoriasis patients can be screened and treated for NAFLD.

Keywords: cirrhosis; non-alcoholic fatty liver disease; psoriasis; quality improvement; transient elastography (fibroscan).